Reunion Neuroscience Inc. (NASDAQ: REUN | TSX: REUN), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that the Company will participate in two upcoming conferences in November.
Hanson Wade 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit
Moderator: Greg Mayes, President & CEO, Reunion Neuroscience
Format: Panel Discussions
- Topic: Guiding Development Strategy to Secure Company Longevity
- Date and Time: Tuesday, November 1 at 9:30 a.m. ET
- Topic: Reflection on Hallucinations & Impact on Efficacy to Guide Development
- Date and Time: Tuesday, November 1 at 3:45 p.m. ET
Jefferies London Healthcare Conference
Speakers: Greg Mayes, President & CEO, Nathan Bryson, Chief Scientific Officer, Reunion Neuroscience
Format: Presentation
- Track 7 – Room: Westminster, Entresol Level
- Date & Time: Wednesday, November 16, at 12:55 – 1:25 p.m. GMT
Management will also take part in one-on-one meetings over the duration of the Jefferies London Healthcare conference. Institutional investors interested in scheduling a meeting with Reunion’s management team, or for more information on the conference, please contact KCSA Strategic Communications at Reunion@kcsa.com.
About Reunion Neuroscience Inc
Reunion (formerly, Field Trip Health Ltd.) is committed to developing innovative therapeutic solutions for mental health conditions. The Company’s lead asset, RE-104 (previously known as FT-104), is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from post-partum and treatment resistant depression. Reunion is also developing the RE-200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.